Form 4: Korro Bio COO Granted 20,132 Restricted Stock Units

Korro Bio's Chief Operating Officer, Todd Chappell, was granted 20,132 restricted stock units vesting over two dates in 2026.

Summary

• Todd Chappell, Chief Operating Officer of Korro Bio, Inc. (KRRO), was granted 20,132 shares of common stock.
• The grant was in the form of Restricted Stock Units (RSUs) under the Issuer's 2023 Stock Option and Incentive Plan.
• The transaction date for this acquisition was December 15, 2025.
• The RSUs will vest in two equal installments: 50% on June 15, 2026, and the remaining 50% on December 15, 2026.
• Vesting is contingent upon Mr. Chappell maintaining a continuous Service Relationship with the company through each vesting date.
• The acquisition price for these RSUs was $0.00, as is typical for RSU grants.
• Following this transaction, Mr. Chappell beneficially owns 20,132 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a routine compensation event, it signifies continued executive alignment with shareholder interests and retention, which are generally favorable for company stability and long-term strategy.

Positives

• The RSU grant aligns the Chief Operating Officer's interests with those of shareholders, incentivizing long-term performance and retention.
• It represents a standard form of equity compensation, indicating ongoing commitment to executive incentives.

Future Outlook

The future outlook indicates that Todd Chappell will acquire beneficial ownership of 20,132 shares of Korro Bio common stock upon the successful completion of the vesting schedule on June 15, 2026, and December 15, 2026, provided he maintains his service relationship with the company.

Industry Context

The grant of Restricted Stock Units (RSUs) to a Chief Operating Officer is a common practice in the biotechnology and pharmaceutical industries, particularly for publicly traded companies like Korro Bio. This form of compensation is widely used to attract, retain, and motivate key executives by linking their long-term financial interests to the company's stock performance.

Comparison to Industry Standards

• The RSU grant to a senior executive like a COO is a standard component of executive compensation packages across the biotech sector, comparable to practices at companies such as Moderna, BioNTech, or CRISPR Therapeutics, which frequently use equity awards to incentivize leadership.
• The vesting schedule, typically spread over several years, is also consistent with industry norms designed to encourage long-term commitment and performance rather than short-term gains.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU grant aligns the COO's financial incentives with the company's long-term performance, potentially benefiting shareholders through improved executive motivation and retention.
• Employees: Standard equity compensation practices can positively influence overall employee morale and perception of fair compensation structures within the company.

Next Steps

• Todd Chappell must maintain a continuous Service Relationship with Korro Bio, Inc. through June 15, 2026, for the first tranche of RSUs to vest.
• Todd Chappell must maintain a continuous Service Relationship with Korro Bio, Inc. through December 15, 2026, for the second tranche of RSUs to vest.

Key Dates

Keywords

Korro Bio, KRRO, Todd Chappell, Restricted Stock Units, RSU grant, insider transaction, Form 4, equity compensation, executive compensation